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Abstract
Colorectal cancer (CRC) is associated with lifestyle factors that affect insulin/IGF signaling, of which the insulin receptor
substrate 1 (IRS1) is a key transducer. We investigated expression, localization and pathologic correlations of IRS1 in cancer-
uninvolved colonic epithelium, primary CRCs with paired liver metastases and in vitro polarizing Caco2 and HT29 cells. IRS1
mRNA and protein resulted higher, relative to paired mucosa, in adenomas of familial adenomatous polyposis patients and
in CRCs that overexpressed c-MYC, ß-catenin, InsRß, and IGF1R. Analysis of IRS1 immunostaining in 24 cases of primary CRC
with paired colonic epithelium and hepatic metastasis showed that staining intensity was significantly higher in metastases
relative to both primary CRC (P,0.01) and colonic epithelium (P,0.01). Primary and metastatic CRCs, compared to colonic
epithelium, contained significantly higher numbers of IRS1-positive cells (P=0.013 and P=0.014, respectively). Pathologic
correlations in 163 primary CRCs revealed that diffuse IRS1 staining was associated with tumors combining differentiated
phenotype and aggressive markers (high Ki67, p53, and ß-catenin). In Caco 2 IRS1 and InsR were maximally expressed after
polarization, while IGF1R was highest in pre-polarized cells. No nuclear IRS1 was detected, while, with polarization,
phosphorylated IRS1 (pIRS1) shifted from the lateral to the apical plasma membrane and was expressed in surface cells only.
In HT29, that carry mutations constitutively activating survival signaling, IRS1 and IGF1R decreased with polarization, while
pIRS1 localized in nuclear spots throughout the course. Overall, these data provide evidence that IRS1 is modulated
according to CRC differentiation, and support a role of IRS1 in CRC progression and liver metastatization.
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Introduction
Colorectal cancer (CRC) has been linked to lifestyle risk factors,
most notably diets based on energy-dense foods and low physical
activity [1–3]. Epidemiological and experimental evidences
indicate that the hormone insulin and the insulin-like growth
factors (IGFs) 1 and 2 play key role(s) in mediating the complex
effect(s) of diet and exercise on CRC risk [4–10]. Over-expression
of the insulin receptor (InsR) and of the closely related IGF1
receptor (IGF1R) is critical for insulin/IGF system over-activation
in cancer [4,7,9]. Intestinal epithelium, that possesses one of the
highest renewal rates among human tissues, expresses both the
InsR and the IGF1R, and the levels of these receptors are higher
in CRC relative to colonic mucosa [4,7,8,11].
Intestinal epithelial differentiation is regulated by several
pathways, particularly ß-catenin-dependent WNT signaling
[12,13]. Most CRCs appear to initiate after inactivating mutations
in the adenomatous polyposis coli (APC) gene, encoding a central
component of the cytosolic multi-protein complex that controls
ß-catenin degradation [14–16]. APC-mutated cells show high
cytoplasmic and nuclear ß-catenin; the latter, after binding to
TCF/LEF transcription factors, forms complexes that, by
switching on several cancer-related genes, impose a proliferative
crypt progenitor phenotype (reviewed at http://www.stanford.
edu/,rnusse/wntwindow.html) [17].
Interestingly, recent evidences link the ß-catenin and the
insulin/IGFs signaling pathways. In fact, IRS1, encoding one of
the two major insulin receptor substrates (IRS1 and IRS2), that
integrate signaling from the InsR, IGF1R and other cytokine and
growth factor receptors [18], is highly upregulated in cells with
exogenously-induced or constitutive ß-catenin signaling [19]. This
seems to depend on direct regulation of IRS1 by TCF/LEF-ß-
catenin complexes. Furthermore, IRS1 is necessary for transfor-
mation in cells that ectopically express oncogenic ß-catenin and for
maintainance of the neoplastic phenotype in APC-mutated cells
[19]. These findings are consistent with earlier evidence that
ectopic IRS1 promotes transformation, while a dominant-negative
IRS1 mutant acts as a tumor suppressor [20]. Furthermore, in the
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irs1 knock-out [21].
In the present study we investigated the expression, localization
and clinicopathologic correlations of IRS1 ex vivo, in cancer-
uninvolved human colonic epithelium, primary CRCs and paired
liver metastases, and in vitro, in two CRC cell models capable of
spontaneous in vitro polarization, Caco2 and HT29 [22,23].
Materials and Methods
Patients and specimens
A formalin-fixed, paraffin-embedded (FFPE) series of 24
primary CRCs with paired cancer-uninvolved colonic mucosa
and synchronous liver metastasis was retrospectively identified at
the Department of Surgical and Oncological Sciences, University
of Palermo, Palermo, Italy. For this series standard whole sections
were used for immunohistochemistry (IHC). An additional FFPE
series, consisting only of primary CRCs, provided by the Digestive
Disease Research Center (DDRC), Tehran University of Medical
Sciences, Tehran, Iran, included 163 of the 205 CRC cases
described in Bishehsari et al. and in Mahdavinia et al. [24,25],
selected based on tissue availability. These CRCs had been
previously characterized for microsatellite instability (MSI) status
and p53 and KRAS mutations [24,25]. Clinico-pathological data,
including age and sex, tumor size, stage and grade, were available
for all 163 patients. No follow-up and survival data were available.
Tissue microarrays (TMAs) were constructed by extracting
histologically-confirmed CRC cores from donor blocks with a
Beecher MTA 2-mm Punch Set (Beecher Instruments, Sun
Prairie, WI, USA). The cores were re-embedded into gridded
paraffin blocks and standard TMA sections were used for IHC.
Samples of tumor and paired colonic mucosa, snap-frozen or
rapidly fixed in RNAlater (Ambion, Applied Biosystems, Foster
City, CA), were collected at the Department of Clinical
Physiopathology, University of Florence, Florence, Italy, from 8
unselected CRC cases and 2 familial adenomatous polyposis (FAP)
patients with molecularly-identified germline APC mutation
(respectively Glu1309fsX1312 and Ser843fsX860). Collection
and analysis of samples and clinico-pathological data were
approved by the G. D’Annunzio University Ethical Committee
and by the Institutional Review Board of the DDRC, Shariati
Hospital, University of Tehran (protocol dated 17/03/2004). All
cases were anonymized.
IHC
TMA and standard whole tissue sections were cut at 4 mma n d
stained with anti-IRS1 rabbit polyclonal (C-20, sc-559, Santa Cruz
Biotechnology, Heidelberg, Germany) at 1:300 dilution for 30 min,
after antigen retrieval by microwave treatment at 750 W for 10 min
in 10 mM sodium citrate buffer pH 6.0 (Dako, Glostrup, Den-
mark). The anti-rabbit EnVision kit (K4003, Dako) was used for
signal amplification. Serial TMA sections were also incubated with
the following mouse monoclonal antibodies: anti-ß-catenin (17C2,
Novocastra Laboratories Ltd, Newcastle, UK), anti-p53 (DO7,
Novocastra) and anti-Ki67 (MIB-1, Dako), for which antigen
retrieval was performed by thermostatic bath at 96uC for 40 min in
sodium citrate buffer (Dako), and anti-EGFR pharmDx (2-18C9,
Dako), according to manufacturer’s instructions. All immunoreac-
tions were revealed by a streptavidin-biotin-enhanced peroxidase
system (Super Sensitive Link-Label IHC Detection System,
BioGenex, Milan, Italy). Positive and negative controls were
included for each antibody and in each batch of staining.
For each marker the percentages of positive cells were estimated
in four fields at 4006 magnification (<1000 cells). IRS1, Ki67,
p53, EGFR and ß-catenin were considered positive when .1% of
the tumor cells were stained, ß-catenin was scored separately for
immunostaining in the cytoplasm, nucleus and along the cell
membrane. The independent samples t-test was used to evaluate
differences in IRS1 expression (% of positive cells) according to
pathological and mutational features. Expression of IRS1 was
correlated to that of each of the other markers by Spearman’s rho
test. The SPSS (version 15.0) program (SPSS Inc., Chicago, IL,
USA) was used for all statistical analyses. All cited P values are
two-sided; P,0.05 was considered as statistically significant.
The density of IRS1 immunostaining in paired cancer-
uninvolved colonic epithelium, primary CRC and liver metastasis
was determined by semiquantitative digital analysis using ImageJ
software (http://rsbweb.nih.gov/ij/). Images were acquired at
standardized bright-field settings (4006magnification). Captured
color jpeg images were converted to greyscale 8 bit images, then
the Region Of Interest manager function was used to outline
cytoplasmic areas, each comprising 5–15 cells. Unwanted nuclear
or stromal elements were edited out. The areas analyzed in 4
matched sets of crypt epithelium, primary CRC and liver
metastasis were 11 for bottom crypt epithelium, 10 for top crypt
epithelium, 78 for total colonic epithelium, 84 for primary CRC,
and 84 for metastatic CRC. Using default ImageJ settings, the
units measured for each area were density value, total area in
square pixels, average size and area fraction. Density values for
crypt epithelium, primary CRC and metastatic CRC, normalized
per area sizes, were analysed using unpaired Student’s t-test. A
value of P,0.05 was considered statistically significant [26].
Quantitative real-time PCR (RTqPCR)
Total RNA from paired mucosa and CRC samples was isolated
with QIAzol (QIAGEN, Hilden, Germany), treated with DNAase-
1 (Ambion), checked by spectrophotometry and agarose gel
electrophoresis, and retro-transcribed with the High Capacity
DNA Archive Kit (Applied Biosystems), following manufacturer’s
instructions. RTqPCR assays were performed in duplicate using
96-well optical reaction plates and an ABI 7500HT machine
(Applied Biosystems). Baseline amplification plot values were set
automatically and thresholds were kept constant to obtain
normalized cycle times and linear regression data. The reaction
mix per well contained 10 ml Power Syber Green (Applied
Biosystems), 2.4 ml of primers (final concentration 150 nM),
4.6 ml RNAase-free water, 3 ml cDNA (60 ng). For all experiments
the PCR protocol was: denaturation at 95uC for 10 min, then 40
cycles at 95uC for 15 sec and at 60uC for 60 sec. Quantification
was performed relative to Cyclophilin [27] using the DDCT method.
Validated RTqPCR primers, designed with Primer Express 3.0
software, were: Cyclophilin,F W5 9TTTCATCTGCACTGCCAA-
GA39; RV59TTGCAAAACACCACATGCT39; IRS1,F W5 9GC-
AACCAGAGTGCCAAAGTGA39 RV59GGAGAAAGTCTCG-
GAGCTATGC39; c-MYC, FW59CCACCACCAGCAGCGACT39,
RV59CAGAAACAACATCGATTTCTTCCTC39.
Cell cultures
Modulation of IRS1 and of the insulin/IGF1 axis was
investigated in the Caco-2 and HT29 CRC cell lines, which,
under specific culture conditions, undergo spontaneous in vitro
differentiation [22,28,29]. Caco-2, developed from a primary
CRC excised from a 72 yrs old male Caucasian, is MSI-stable and
carries an inactivating APC point mutation, with second hit by loss
of heterozygosity (LOH), a missense mutation in ß-catenin exon 5
(which does not appear to affect degradation), and is wild-type for
KRAS, BRAF, PIK3CA and PTEN [23,30–32]. HT29, developed
from a primary CRC excised from a 44 yrs old female Caucasian,
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mutations (which still allow limited ß-catenin phosphorylation
and ubiquitination), as well as mutations in SMAD4, BRAF, TP53,
and PI3KCA, encoding the p110a catalytic subunit of the class I
phosphatidylinositol 3-kinases (PI3K) [23,31] (see also the
Catalogue of Somatic Mutations in Cancer, http://www.sanger.
ac.uk/cosmic).
Caco-2 and HT29 cells were obtained from ATCC (ATCC-
LGC Promochem, London UK). Caco-2 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS), L-glutamine (2 mM), penicillin (100 units/
ml), and streptomycin (100 mg/ml) under a humidified atmosphere
with 5% CO2 at 37uC. Cells were plated on 10 cm Petri dishes
and allowed to grow at confluency. Upon confluency (designated
as zero time point) Caco-2 culture was carried out in DMEM with
20% FBS. The entire time course was performed twice and whole
cell lysates were obtained at 3, 7 and 14 days from confluency.
HT29 cells were maintained in DMEM with 10% FBS and
allowed to grow for 3 (preconfluent), 7 (confluent) and 14 (post-
confluent) days, at which times whole cell lysates were obtained.
Western blotting
Whole cell or whole tissue lysates were prepared using ice-cold
lysis buffer (100 mM NaCl, 10 mM EDTA, 1% TritonX-100,
50 mM Hepes pH 7.9, 10 mM NaF, 4 mM sodium pyrophos-
phate, 2 mM Na3VO4) supplemented with protease inhibitors
(1 mM phenylmethylsulphonylfluoride, 2 mg/ml aprotinin, 2 mg/
ml leupeptin). Lysates were cleared by centrifugation (100006 g
for 20 min) and protein content was determined by the Bradford
method. Fifty micrograms (50 mg) of total proteins were resolved
under reducing conditions on 7.5% SDS-PAGE and transferred to
reinforced nitrocellulose. The membrane was blocked with 3%
not-fat dry milk in PBS with 0.01% Tween 20 for 1 hr at room
temperature and then incubated overnight with the following
primary antibodies: anti-IRS1 rabbit polyclonal (C-20, Santa
Cruz), diluted 1:500; anti-tyrosine 632-phosphorylated IRS1
(pIRS1 Tyr632) polyclonal antibody (Santa Cruz), diluted 1:200;
anti-ß-catenin monoclonal (Ylem, Rome, Italy), diluted 1:50 or
anti-ß-catenin polyclonal (#9562, Cell Signaling, Danvers, MA,
USA), diluted 1:1000; polyclonal against the ß subunit of the InsR
(InsRß) (C-19, Santa Cruz) diluted 1:200; polyclonal against the ß
subunit of the IGF1R (anti-IGF1Rß, Cell Signaling Technology/
Euroclone, Milan, Italy) diluted 1:800; anti-actin monoclonal
(Sigma-Aldrich, Milan, Italy) diluted 1:10000. The membrane was
then washed in PBS and incubated for 1 h at room temperature
with the corresponding horseradish peroxidase-conjugated sec-
ondary antibody, diluted 1:2000 (Ge Healthcare, Milan, Italy).
Bound antibodies were detected using the enhanced chemilumi-
nescent (ECL) method (Pierce-Celbio, Pero, Italy). Quantification
of western blot signals (mean 6 SE from at least two independent
experiments) was obtained analyzing digitized signals with ImageJ
software (http://rsbweb.nih.gov/ij/). The data were normalized
for ß-actin and expressed as percentage of the maximum value.
Immunofluorescence
Caco-2 and HT29 cells, grown on coverslips under the
conditions described above, were fixed in methanol (220uC) and
incubated with anti-ß-catenin monoclonal (BD Science, Franklin
Lakes, NJ, USA), anti-IRS1 rabbit polyclonal (C-20, Santa Cruz),
diluted 1:50; and anti-pIRS1 (Tyr632) polyclonal (Santa Cruz),
diluted 1:50. Nuclei were stained with 4,6-diamido-2-phenylindole
(DAPI, Sigma-Aldrich) and cell membranes with wheat germ
agglutinin (WGA, Sigma-Aldrich). Primary antibodies were
visualized using goat anti-mouse IgG fluorescein isothiocyanate-
conjugated (Cappel, MP Biomedicals Europe, Illkirch, France) or
goat anti-rabbit IgG-Texas-Red-conjugated (Jackson ImmunoR-
esearch Laboratories Europe, Newmarket, Suffolk, UK) for
30 min at room temperature. Cells were analyzed using an
Apotome Axio Observer Z1 inverted microscope (Zeiss, Oberko-
chen, Germany) equipped with an AxioCam MRM Rev.3 at 406
magnification. Colocalization of the fluorescence signals was
analyzed with AxioVision 4.6.3 software. Image analysis was
performed using Adobe Photoshop.
Electron microscopy
Cells were fixed in a mixture of 2% paraformaldehyde-2%
glutaraldehyde in PBS (pH 7.4), post-fixed in 1% osmium
tetroxide in veronal acetate buffer (pH 7.4) for 1 h at 25uC,
stained with 0.1% tannic acid in the same buffer for 30 min at
25uC and with uranyl acetate (5 mg/ml) for 1 h at 25uC,
dehydrated in acetone and embedded in Epon 812. Thin sections
were finally examined under a Philips CM10 transmission electron
microscope, after post-staining with uranyl acetate and lead
citrate.
Results
IRS1 in CRC
We determined by RTqPCR the constitutive expression of IRS1
and of c-MYC, key WNT target and effector [17], in total RNA
from paired colorectal mucosa and CRC samples (Figure 1A). Five
CRCs overexpressed IRS1 relative to paired mucosa. Overall, the
mRNA levels of IRS1 were in good agreement with those of c-
MYC.
To explore the modulation of IRS1 and of other insulin/IGF
pathway components, we assessed by western blot the protein
levels of IRS1, InsRß, IGF1Rß and ß-catenin in 7 of the 8 above-
reported CRC cases (for which tissue was available), and in paired
colonic mucosa and adenoma samples from two unrelated FAP
patients [33]. In the primary CRCs the IRS1 protein levels
reflected the mRNA levels, being higher, relative to paired
mucosa, in 4 of the 5 cases that overexpressed IRS1 and c-MYC
mRNA. These CRCs also overexpressed InsRß, IGF1R, and ß-
catenin, while in the other cases the mucosal levels of InsRß,
IGF1R, and ß-catenin were similar or above those of the paired
CRC (Figure 1B–C). In the two FAP cases, IRS1 markedly
increased in the adenoma relative to mucosa, together with InsRß,
IGF1Rß and ß-catenin, and IHC showed diffuse IRS1 in
adenomas (Figure S1).
We further assessed IRS1 protein expression by IHC in
individually-matched paraffin-embedded sections of colonic mu-
cosa, primary and metastatic CRC. Twenty-four cases with paired
primary CRC and liver metastasis, also including cancer-
uninvolved colonic mucosa, were available for analysis. Immuno-
reactive IRS1 was clearly detectable in crypt epithelium, as well as
in primary and metastatic CRC (Figure 2A–E). Primary and
metastatic tumors, when compared to colonic epithelium,
contained higher numbers of cells expressing IRS1 (80.866.2%
for primary and 81.366.6% for metastatic CRC versus
59.165.6% for colonic epithelium, P=0.013 and P=0.014,
respectively, Figure 2F). Density values of pixels for IRS1, as
quantified using ImageJ software, did not differ between primary
CRC and colonic epithelium, but were significantly higher in liver
metastases compared to CRC (P,0.01) and colonic epithelium
(P,0.01) (Table 1). Differences in density values of IRS1 between
colonic epithelium of bottom and top crypt were not significant.
We further explored the pathologic correlations of IRS1
expression in a series of 163 primary CRCs tested by IHC on
IRS1 in Colorectal Cancer
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e36190Figure 1. mRNA and protein levels of IRS1, c-MYC, insRß, IGF1R and ß-catenin in paired colonic mucosa and primary colorectal
cancer (CRC). Panel A shows histograms of the relative expression of IRS1 (left) and c-MYC (right) transcripts in paired samples of cancer-unaffected
colorectal mucosa (white) and CRC (black), as determined by quantitative real-time PCR (RTqPCR). Mucosa samples were set equal to 100% and
normalized to the relative expression of the housekeeping gene, Cyclophilin. Cancer samples were expressed relative to mucosa and normalized to
the relative expression of the housekeeping gene. In pairs M1T1 to M4T4 and in M8T8, both c-MYC and IRS1 increase in CRC relative to mucosa, only
in M5T5 and M6T6 IRS1 and c-MYC disagree (IRS1: P=0.05, c-MYC: P,0.001, unpaired t test on the means of all differences, data not shown). Panel B
shows western blot analysis of IRS1, beta subunit of the insulin receptor (InsRß), beta subunit of the insulin-like growth factor 1 receptor (IGF1Rß),ß -
catenin and ß-actin, as loading control, in the paired colonic mucosa and CRC samples shown in A (except M6T6, for which tissue for western blot
analysis was not available). The histograms in Panel C show quantitations, after normalization for ß-actin, of the IRS1, InsRß, IGF1Rß and ß-catenin
signals. Relative to paired mucosa, IRS1 is overexpressed in the CRCs of pairs M1T1-M4T4, together with InsRß, IGF1Rß and ß-catenin (IRS1: P=0.017,
InsRß: P=0.044, IGF1Rß: P,0.001, ß-catenin: P,0.001, unpaired t test on the means of all differences, data not shown). Notably, the CRCs that
overexpressed the IRS1, InsRß, IGF1Rß and ß-catenin proteins also overexpressed IRS1 and c-MYC mRNA.
doi:10.1371/journal.pone.0036190.g001
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positive. IRS1 expression did not significantly differ in relation to
age at diagnosis, gender, tumor location (right versus left colon),
Duke’s stage, and MSI status. However, CRCs with high/
moderate differentiation were more likely to show high percent-
ages of IRS1-positive cells than poorly-differentiated tumors
(P=0.001), while CRCs with mucinous/signet-ring phenotype
were associated with focal or no IRS1 (P,0.001). Poorly
differentiated CRCs often manifested nuclear staining in addition
to cytoplasmic reactivity. Figure 3A–E exemplifies IRS1 staining
patterns.
As shown in Table 3, which reports Spearman’s correlations
between IHC markers, IRS1 was positively associated with Ki67
(P=0.008), p53 (P=0.032), membrane (P=0.001) and cytoplas-
mic (P,0.001) ß-catenin. Other associations involved cell
membrane ß-catenin, positively correlated with cytoplasmic ß-
catenin (P,0.001) and EGFR (P=0.005), and cytoplasmic ß-
catenin, positively correlated with nuclear ß-catenin (P,0.001),
Ki67 (P=0.002) and p53 (P=0.009), while nuclear ß-catenin
positively correlated with p53 (P=0.049). Predictably, a positive
correlation was found between Ki67 and p53 (P=0.029).
These results suggest that high IRS1 is associated with CRCs
combining well/moderately differentiated histological phenotype
with immunohistochemical markers of poor prognosis (expression
of Ki67, p53, and cytoplasmic ß-catenin).
IRS1 in Caco-2 polarization
Caco-2 carries an inactivating APC mutation with second hit by
LOH, but is known to be negative for mutations in KRAS, BRAF,
PIK3CA and PTEN [23,31] (see also COSMIC, http://www.
sanger.ac.uk/cosmic). Caco-2 cells are capable of spontaneous
differentiation, documented by the expression of microvilli,
enzymes and transporters characteristic of polarized enterocytes
and by the development of tight junctions, which, in the in vivo
Figure 2. IRS1 immunostaining in cancer-uninvolved colonic epithelium, primary colorectal cancer and paired synchronous liver
metastases. Panel A shows IRS1 immunostaining in full-length longitudinal sections of cancer-uninvolved colonic crypts. Panels B–E provide an
example of IRS1 immunostaining in primary CRC (B–C) versus paired metastasis (liver biopsy core, D–E). Both show diffuse cytoplasmic IRS1, with
much stronger immunostaining in metastatic cells. Panel F shows the histograms of the mean percentages of IRS1-positive cells in 24 cases of
matching non-neoplastic colon epithelium, primary CRC and metastatic CRC (error bars mean 6 SEM). There were significant differences between
colonic epithelium (59.165.6%) and primary CRC (80.866.2%, P=0.013 by independent sample t test) and between epithelium (59.165.6%) and
hepatic metastasis (81.366.6%, P=0.014). The difference between primary and metastatic CRC was not significant (P=0.964).
doi:10.1371/journal.pone.0036190.g002
IRS1 in Colorectal Cancer
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toward the mucosal surface [28,29,34]. IRS1 expression and
activation was analyzed by western blot in Caco-2 cultures during
polarization at 3, 7 and 14 days after confluency, in presence and
in absence of serum, together with expression of InsRß and
IGF1Rß (Figure 4A). Under both culture conditions IRS1
decreased at day 7, but increased subsequently, with highest
expression at day 14. Notably, in both normal and serum-free
cultures, InsRß resulted weakly expressed at day 3 and
significantly increased at day 7, with maximum expression at
day 14. Inversely, again under both conditions, IGF1Rß was
highest at day 3 and dramatically decreased at days 7 and 14. To
assess IRS1 activation, Caco-2 cells at 3, 7 and 14 days from
confluency were serum-starved overnight and then stimulated with
or without insulin (100 nM) or IGF1 (10 nM) for 5 min. Total
protein lysates (80 mg) obtained after 5 min of treatment were
resolved and blotted with anti-pIRS1 Tyr632 (Figure 4G). IRS1
tyrosine phosphorylation was relevant at day 7 of polarization and
did not appear to be modulated by exogenous insulin or IGF1
(lane 4–6). However, at day 3, only exogenous IGF1 activated
IRS1. These data suggest that IRS1 could mediate autocrinely-
activated InsR signaling in polarized cells (where IRS1 and InsRß
are maximally expressed and IGF1Rß is lowest), and IGF1R
signaling, activated by exogenous IGFs, in pre-polarized cells
(where IRS1 is expressed at lower level and IGF1Rß and InsRß at
highest and lowest levels, respectively).
Transmission electron microscopy of the Caco-2 cultures
documented at day 3 the formation of localized electron-dense
areas of close opposition between adjacent lateral plasma
membranes, characteristic of forming tight junctions, and at day
14 the presence of complete intercellular junctional complexes, as
well as polarization of the absorptive apical brush border
(Figure 4B–F). Overall, this confirmed enterocytic polarization
during the culture time course [28].
Immunofluorescence analysis demonstrated differences in the
subcellular distribution of total IRS1 and of pIRS1 Tyr632 during
the Caco-2 culture time course (Figure 5). At day 3 IRS1
immunolabeling was distinctly less intense than at days 7 and 14,
and was predominantly localized along the lateral and basolateral
cell membranes. Merging of the ß-catenin and IRS1 images
confirmed the colocalization of the two proteins along the
basolateral membranes. At day 3 staining of pIRS1 Tyr632 was
relatively weak and had a distribution similar to that of total IRS1.
At day 7 pIRS1 Tyr632 increased and mostly appeared as
punctate staining on top of surface cells, suggestive of localization
beneath the plasma membrane on the apical side. Total IRS1
remained predominantly localized along the basolateral mem-
branes, together with ß-catenin. Notably, at day 14 pIRS1 Tyr632
was restricted to fewer surface cells, which, however, appeared
more strongly labeled than at day 7, with the typical apical plasma
membrane punctate pattern (the lower number of positive cells
was consistent with the decrease in pIRS1 Tyr632 at day 14 by
western blot). No nuclear staining for IRS1, pIRS1 Tyr632 or ß-
catenin was observed during Caco-2 cell polarization.
In conclusion, the immunofluorescence data indicate that in the
Caco-2 model the intensity of IRS1 and pIRS1 staining increases
with polarization, and that, during such process, pIRS1 Tyr632
becomes expressed in surface cells only, switching in subcellular
distribution from the cytoplasm and basolateral membranes, where
it colocalizes with ß-catenin, to the apical plasma membranes. This
Table 1. Density of IRS1 immunostaining in paired colonic
epithelium, primary colorectal cancer and synchronous liver
metastasis.
Sample type Mean ± SEM P
Bottom crypt (11)* 39.1062.9
Top crypt (10) 45.4062.16 0.15
Total colonic epithelium (78) 42.0061.60
Primary CRC (84) 44.5060.99 0.36
Total colonic epithelium (78) 42.0061.60
Liver metastasis(84) 70.3862.6 ,0.01
Primary CRC (84) 44.5060.99
Liver metastasis(84) 70.3862.60 ,0.01
Density values (mean 6 SEM), normalized per area size in square pixels, were
obtained by digital analysis using ImageJ software (http://rsbweb.nih.gov/ij/)
for IRS1 staining in: bottom versus top colonic crypt epithelium (respectively 11
and 10 areas); total colonic epithelium (78 areas) versus primary CRC (84 areas);
total colonic epithelium (78 areas) versus liver metastasis (84 areas); primary
CRC versus liver metastasis (84 areas). Only the differences between total
colonic epithelium and liver metastasis and between primary CRC and liver
metastasis are significant (P,0.01).
*Number of examined areas, CRC: colorectal cancer.
doi:10.1371/journal.pone.0036190.t001
Table 2. Independent samples t-test of IRS1 expression
according to the individual and pathological features of the
primary colorectal cancer cases (n=163).
% IRS1 positive cells
Variable n (%) mean ± SE P
Age at diagnosis (yr)
#40 60 (36.8) 79.064.2 0.144
.40 103 (63.2) 86.162.4
Gender
Male 90 (55.2) 83.262.9 0.877
Female 73 (44.8) 83.963.3
Tumor location
Right colon 58 (35.6) 78.664.3 0.168
Left colon/rectum 105 (64.4) 85.662.5
Differentiation
Well+Moderate 138 (84.7) 88.161.9 0.001
Poor 25 (15.3) 58.068.2
Duke’s stage
A+B 91 (55.8) 85.762.8 0.252
C+D 72 (44.2) 80.763.5
Mucinous*
Yes 42 (25.8) 67.166.1 0.001
No 121 (74.2) 89.261.8
MSI
Absent 124 (76.1) 84.362.5 0.536
Present 39 (23.9) 81.264.7
KRAS{
Wild-type 98 (65.8) 82.063.0 0.442
Mutated 51 (34.2) 85.863.4
*comprising mucinous and signet-ring carcinomas;
{KRAS mutations data not available for 14 cases. Significant correlations
(p,0.05) in bold.
doi:10.1371/journal.pone.0036190.t002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36190parallelsthe tightening oftheintercellularjunctions,asevidencedby
electron microscopy, which makes the basolateral membranes
inaccessible to freely-diffusing extracellular molecules.
IRS1 in HT29 polarization
HT-29 cells carry double-hit APC mutations, as well as
mutations in SMAD4, BRAF, TP53, and, particularly, PI3KCA,
which constitutively activate and deregulate intracellular signaling
[23,31] (see also COSMIC, http://www.sanger.ac.uk/cosmic).
Therefore HT29 cells provide a distinct in vitro model for the study
of intestinal epithelial differentiation and polarity [22,29].
IRS1 protein expression was analyzed by western blotting in
HT29 cultures during spontaneous polarization, together with the
InsRß and IGF1Rß subunit proteins. Western blot analysis
showed that IRS1 levels were highest at day 3 (pre-confluent)
and markedly decreased at day 7 (confluent), with only a slight
increase (relative to day 7) at day 14 (post-confluent) (Figure 6A).
IGF1Rß was similarly modulated, showing highest expression at
day 3, marked decrease at day 7, and only slight increase (relative
to day 7) at day 14. InsRß, low at day 3 and lowest at day 7,
strongly increased at day 14. ß-catenin demonstrated little
modulation, with slightly higher level at day 14 (post-confluent).
Transmission electron microscopy analysis of pre-confluent (day
3), confluent (day 7) and post-confluent (day 14) HT29 cells
demonstrated gradual polarization during the time course
(Figure 6B–D). Formation of localized electron-dense areas of
close opposition between the lateral plasma membranes of
adjacent cells, characteristic of forming intercellular junctions,
was evident at day 7, and tight junctions, including zonula
adherens and desmosomes, were evident at day 14, together with
functional apical polarization of the microvilli.
Immunofluorescence analysis clearly revealed that in pre-
confluent, and, with lesser intensity, post-confluent HT29 cells
IRS1 was detectable in the cytoplasm, particularly in the
perinuclear region, as well as in discrete spots within the nuclei
(Figure 7). Nuclear IRS1 was confirmed by double labeling with
Figure 3. IRS1 and tumor histotype in primary colorectal cancer. Panels A and B respectively show diffuse cytoplasmic IRS1 in non-mucinous
colorectal CRCs, including a moderately differentiated tumor, with strong immunostaining of cancer cells, and a poorly differentiated tumor, with
weaker and possibly also nuclear IRS1 (arrowheads). Panels C–E show a poorly differentiated CRC with mucinous, mostly signet-ring phenotype.
Notably, in the marginal area (single asterisk) detailed in panel D, tumor cells with non-mucinous phenotype show nuclear/perinuclear IRS1
(arrowheads), whereas signet-ring cells floating in mucin (double asterisk), detailed in panel E, do not show IRS1 immunostaining.
doi:10.1371/journal.pone.0036190.g003
Table 3. Spearman’s correlations among IRS1, Ki67, p53,
EGFR and ß-catenin in the primary colorectal cancer cases
(n=163).
IRS-1 Ki-67 p53 EGFR ßCat M ßCat C ßCat N
IRS1
Rho 1 0.213 0.168 20.030 0.263 0.360 0.128
P 0.008 0.032 0.709 0.001 0.000 0.107
Ki67
Rho 0.213 1 0.176 20.049 0.082 0.251 0.074
P 0.008 0.029 0.554 0.311 0.002 0.361
p53
Rho 0.168 0.176 1 20.088 0.108 0.205 0.156
P 0.032 0.029 0.277 0.175 0.009 0.049
EGFR
Rho 20.030 20.049 20.088 1 0.222 0.037 0.156
P 0.709 0.554 0.277 0.005 0.645 0.050
ßCat M
Rho 0.263 0.082 0.108 0.222 1 0.509 20.088
P 0.001 0.311 0.175 0.005 0.000 0.267
ßCat C
Rho 0.360 0.251 0.205 0.037 0.509 1 0.491
P 0.000 0.002 0.009 0.645 0.000 0.000
ßCat N
Rho 0.128 0.074 0.156 20.157 20.088 0.491 1
P 0.107 0.361 0.049 0.050 0.267 0.000
Abbreviations: ßCat: ß-catenin; EGFR: epidermal growth factor receptor; M:
membrane staining; C: cytoplasmic staining; N: nuclear staining; Rho:
Spearman’s coefficient correlation. Significant correlations (P,0.05) in bold.
doi:10.1371/journal.pone.0036190.t003
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e36190Figure 4. Expression of IRS1, insulin receptor, IGF1 receptor and ultrastructural differentiation in polarizing Caco-2 cells. Panel A
shows western blot analysis of IRS1, beta subunit of the insulin receptor (InsRß), beta subunit of the insulin-like growth factor 1 receptor (IGF1Rß) and
ß-actin, as loading control, in Caco-2 cells at days 3, 7 and 14 post-confluence, duplicated in absence (2) and presence (+) of serum in the culture
medium. The histograms show quantitations, after normalization for ß-actin, of the IRS1, InsRß and IGF1Rß signals (means 6 SE from the two
experiments). Under both culture conditions increased espression of IRS1 and InsRß is clearly evident in polarized cells at day 14 (IRS1) and at days 7
and 14 (InsRß), whereas maximum expression of IGF1Rß is detected only at day 3. Transmission electron microscopy of Caco-2 cells at day 3 of the
spontaneous polarization time course reveals forming electron-dense junctions at the apex of the lateral membranes of adjacent cells (panel A,
arrow). With progression of polarization, tight junctions and desmosomes (panels C–D, arrows) and adhesion junctions (panel D) become evident as
electron-dense plaques on adjacent lateral membranes at days 7 and 14, respectively. In addition, tight multicellular clusters, with differentiation
features, such as intracellular lumina rich of apical brush border (panels E–F), become evident at day 14. Abbreviations: tj, tight junction; ad, adhesion
junction; ds, desmosome. Panel G shows western blot levels of tyrosine 632-phosphorylated IRS1 (IRS1tyr632) and, as loading control, ß-actin, in
serum-starved Caco-2 cells unstimulated (2) and stimulated (+) with insulin (100 nM) or IGF1 (10 nM). IRS1 tyrosine phosphorylation is relevant at
day 7 of polarization, independently from the addition of exogenous insulin or IGF1. However, at day 3, only exogenous IGF1 determines IRS1
phosphorylation.
doi:10.1371/journal.pone.0036190.g004
IRS1 in Colorectal Cancer
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36190IRS1 and the membrane marker WGA. Interestingly, pIRS1
Tyr632, which appeared as discrete dots, was almost exclusively
localized in the nuclei and did not change between pre- and post-
confluent cells. At both culture time points, ß-catenin was present
in the nucleus, as well as in the cytoplasm and along the lateral
membranes. IRS1 did not colocalize with ß-catenin in pre-
confluent cells, while some colocalization signals, only in the
cytoplasm, were observed in post-confluent cells.
These data indicate that in HT29 cells, known to carry
mutations that constitutively activate intracellular signaling, IRS1
Figure 5. Subcellular localizations of IRS1, p-IRS1 and ß-catenin during Caco-2 polarization. Apotome immunofluorescence analysis at
days 3, 7, and 14 postconfluency demonstrates differences in the cellular distribution of total IRS1 (IRS1, green), tyrosine 632-phosphorylated IRS1
(pIRS1, green), and ß-catenin (red) during the Caco-2 culture time course. For each field, the nuclei are counterstained in blue with 49,6-diamidino-2-
phenylindole (DAPI). Overlaps between red and green signals (merge) point to co-localizations (in yellow) of IRS1/pIRS1 and ß-catenin. Bar=20 mm.
doi:10.1371/journal.pone.0036190.g005
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e36190is highest in pre-confluent cells and pIRS1 localizes in discrete
nuclear spots, with little variation during the polarization course.
Discussion
Of the 3 human IRS genes, IRS1, IRS2 and IRS4, the
ubiquitously expressed IRS1 and IRS2 mediate the major
metabolic, proliferative and anti-apoptotic functions of InsR and
IGF1R signaling [18]. Tyrosine-phosphorylated IRS1/2 bind Src
homology 2 (SH2) proteins, such as the p85 subunit of the PI3K,
the phosphotyrosine phosphatase SHP-2, the Src-like kinases Fyn,
Grb-2, NCK, CRK, SHB, and others. These activate downstream
effectors, such as the mitogen-activated protein kinase (MAPK)
and the PI3K pathways, which promote survival, proliferation,
differentiation and metabolic responses [18].
We previously showed that IRS2 is directly controlled by the
caudal-related homeobox protein 2 (CDX2) and significantly
expressed in top crypt intestinal epithelium [27]. IRS2 RNA
increases with spontaneous differentiation in both HT29 and
Caco-2 cells and is downregulated in ß-catenin-dependent
intestinal tumorigenesis [33].
In contrast, several lines of evidence, summarized in the
introduction, implicate IRS1 in intestinal carcinogenesis, under
the direct control of TCF/LEF-ß-catenin complexes [19–21]. It is
also well known that endogenous IRS1 is overexpressed and
constitutively activated in a variety of human cancers [34].
In the present study, IRS1 mRNA and protein levels resulted
higher, relative to paired mucosa, in CRCs that overexpressed c-
MYC, ß-catenin, InsRß, and IGF1R. Overexpression of IRS1,
together with ß-catenin, InsRß, and IGF1R, in FAP-associated
adenomas was in agreement with data reported for the Apc(Min/+)
mouse model [21,35]. By IHC, IRS1 resulted expressed throughout
the colonic crypt, which could be consistent with a role of InsR/
IGF1R signaling in intestinal epithelial differentiation [36–37].
Figure 6. Expression levels of IRS1, insulin receptor, IGF1 receptor, ß-catenin and ultrastructural differentiation in polarizing HT29
cells. Panel A shows western blot analysis of IRS1, beta subunit of the insulin receptor (InsRß), ß-catenin, beta subunit of the insulin-like growth
factor 1 receptor (IGF1Rß), and ß-actin, as loading control, in HT29 cells maintained in complete medium during spontaneous differentiation at days 3
(pre-confluent), 7 (confluent) and 14 (post-confluent). The histograms show quantitations, after normalization for ß-actin, of the IRS1, InsRß, ß-catenin
and IGF1Rß protein signals (means 6 SE from two independent experiments). Expression of IRS1 and IGF1Rß is highest at day 3 and markedly
declines at days 7 and 14, whereas InsRß is maximally expressed at day 14. At day 3, transmission electron microscopy of HT29 cells reveals bundles of
intermediated filaments converging towards the plasma membrane to form electron-dense junctions between adjacent cell membranes (panel B–B1,
arrow). With progression of the time-course, HT29 cells display differentiated features, such as desmosomes at days 7 and 14 (panel C–C1, arrow, and
D–D1, arrow) and tight junctions at day 14 (D–D1, arrow). Abbreviations: tj, tight junction; ad, adhesion junction; ds, desmosome.
doi:10.1371/journal.pone.0036190.g006
IRS1 in Colorectal Cancer
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e36190The immunostaining of the primary CRCs was in the range of
that of the cancer-uninvolved top crypt in terms of intensity, but
more diffuse in terms of percentages of positive cells, which may
account for the above-discussed higher mRNA and protein levels
in CRC relative to mucosa. In the hepatic metastases, IRS1
positivity was similar to that of the primary tumors in percentages
of stained cells, but the staining intensity resulted significantly
higher. The increase of IRS1 staining intensity in hepatic
metastases is consistent with the fact that the liver is the major
site of IGFs synthesis [38]. Furthermore, it has been shown that
metastatic CRC cells express high IGF1R and that IRS1 promotes
liver metastatization [38–41].
Human CRC is a molecularly heterogeneous disease [42–45].
To investigate associations with pathological characteristics, we
Figure 7. Subcellular localizations of IRS1, p-IRS1 and ß-catenin during HT29 polarization. Panels A–D show Apotome
immunofluorescence analysis of HT29 cells at days 3 (pre-confluent), 7 (confluent) and 14 (post-confluent). This demonstrates differences in the
cellular distribution of total IRS1 (IRS1, green), tyrosine 632-phosphorylated IRS1 (pIRS1, green, mainly nuclear dots), and ß-catenin (red) during the
culture time course. For each field, the nuclei are counterstained in blue with 49,6-diamidino-2-phenylindole (DAPI). Overlaps between red and green
signals (yellow) point to co-localizations of IRS1/pIRS1 and ß-catenin. This does not appear to involve the nuclear localizations, where IRS1 mainly
appears as green dots and ß-catenin mainly as purple to bluish-violet blotches. Panel E highlights nuclear IRS1 (red, discrete dots) by double labeling
of HT29 cells with the membrane marker wheat germ agglutinin (WGA, green). Bars=20 mm.
doi:10.1371/journal.pone.0036190.g007
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TMA IHC. In terms of percentages of positive cells, IRS1
correlated with moderately/well-differentiated phenotype, but was
also associated with markers of proliferative activity/biological
aggressiveness (Ki67, p53, and cytoplasmic ß-catenin). In this
regard, it is well recognized that the moderately to well-
differentiated CRC subset includes tumors with a spectrum of
histological variation and with different metastatic potentials [46].
Moreover, it has been shown that resistance to apoptosis identifies
CRCs that, independently of clinicopathological variables (includ-
ing grade of histological differentiation), have poor outcomes [47].
Signaling through the IGF/INS/IRS axis has a key anti-apoptotic
role [48]. Further studies are needed to verify whether IRS1
concurs in identifying CRCs that, independently of classic
pathological variables, have poor prognosis because of selective
advantages during tumor progression [49].
Unlike Bommer et al. [19], who reported an enrichment of
mucinous histotype in their high-IRS1 CRC subset, in our study
mucinous/signet ring CRCs expressed significantly less IRS1 than
non-mucinous tumors. In this regard, our findings are coherent
with our evidence that IRS1 labeling correlates with moderately/
well-differentiated phenotype and with the fact that mucinous/
signet ring CRCs tend to be poorly differentiated [50].
To correlate IRS1 with differentiation in in vitro CRC models,
we investigated the expression of IRS1, InsRß and IGF1R in
Caco-2 and HT29 cells. In Caco-2, that mimics crypt to villus axis
differentiation [28–29], IRS1 and InsRß reached maximum levels
at completion of polarization, while IGF1Rß was maximally
expressed in pre-polarized cells. This suggests that IRS1 could
mainly mediate IGF1R signaling before polarization and InsR
signaling with polarization, together with IRS2, also highly
expressed in polarized Caco-2 cells [27,51]. No nuclear IRS1
was detected, while, with polarization, pIRS1 Tyr632 was
expressed only in surface cells, switching from the lateral to the
apical plasma membrane. This process paralleled the tightening of
the intercellular junctions evidenced by electron microscopy,
suggesting that IRS1 migrated from intercellular membranes that,
due to close-fitting contact, became inaccessible to exogenous
signaling, to free apical membranes. Notably, this sub-apical
localization is consistent with the fact that in polarized Caco-2 cells
InsR and IGF1R are implicated in the regulation of Na+ glucose
transport across the brush border, as in functional intestinal
epithelium, and with evidence that in polarized epithelia insulin is
in the apical fluid and InsR at the apical membrane [52–54]. Thus
the Caco-2 model supports the view that cytoplasmic IRS1
expression correlates with differentiation, as observed by immu-
nohistochemistry in primary CRCs.
In HT29 cells, where a gain of function PI3KCA mutation
cooperates with other mutations in increasing proliferative and
survival capacities [7,43,44,55], total IRS1 decreased with
polarization and pIRS1, that did not appreciably vary, localized
mainly in discrete nuclear spots, in contrast with the sub-apical
location seen in polarized Caco-2 cells. This nuclear localization
could be relevant, as IRS1 inhibition attenuates tumorigenicity in
HT29 cells, that express low cytoplasmic IRS1 [19]. Following
oncogene activation or IGF1 treatment, IRS1 is known to
translocate in the nucleus [56–60], where it might be involved in
ß-catenin translocation [61] and/or act as a transcription factor
[57]. Furthermore, activated IGF1R has been recently shown to
translocate to the nucleus in both non-malignant tissues and
cancers [62–63], although it remains to be determined whether
IRS1 and IGF1R interact in this subcellular location. Thus, the
low IRS1 expression seen in HT29 cells could reflect that observed
in the poorly differentiated primary CRCs, including mucinous/
signet ring tumors, and could be related to nuclear trafficking and
functions.
In conclusion, our results provide further evidence that IRS1 is
differentially modulated, together with InsRß, IGF1R, and ß-
catenin, during differentiation in the Caco-2 and HT29 cell
models and ex vivo in primary CRCs versus mucosa. Furthermore,
diffuse IRS1 appears to be associated with CRCs that, despite
their moderately to well differentiated histologic features, express
markers of biological aggressiveness. The increase in IRS1
immunostaining in hepatic secondaries is consistent with a possible
role in liver metastatization [38–41]. Unfortunately, follow-up
data for our patients were not available. Therefore, the prognostic
value of IRS1 expression in CRC could not be assessed. This is a
limitation of the present study, which needs to be addressed in
future investigations.
Supporting Information
Figure S1 IRS1, insulin receptor, IGF1 receptor and ß-
catenin in colonic mucosa and adenomas from familial
adenomatous polyposis coli (FAP) patients. Panel A
compares the western blot expression levels of IRS1, beta subunit
of the insulin receptor (InsRß), beta subunit of the insulin-like
growth factor 1 receptor (IGF1Rß), ß-catenin and, as loading
control, ß-actin, in paired mucosa (M) and adenoma (T) samples
from two unrelated FAP patients. In both cases, the levels of IRS1,
InsRß, IGF1Rß, and ß-catenin are distinctly higher in the
adenoma versus the paired mucosa sample. Panel B, detailing
the edge of an adenoma, highlights the difference in IRS1
immunostaining associated with the transition between normal-
appearing (downward pointing arrow) and dysplastic (upward
pointing arrow) colonic crypts. The hyperplastic and mucin-
depleted epithelium of the dysplastic crypts shows diffuse
cytoplasmic IRS1, while mostly perinuclear/nuclear IRS1 is
evident in non-dysplastic crypts. Panel C shows diffuse cytoplasmic
IRS1 in a severely dysplastic adenoma.
(TIF)
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